A Fully Implantable Self Powered Extra Aortic Counterpulsation Device? For Translational Development In Hypertensive Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$901,586.00
Summary
The development of a low cost self-powered cardiac aortic assist device to improve blood flow to the heart and rest of the body. The device is placed on the external surface of the large blood vessel (aorta) leaving the heart and provides gentle counterpulsation to improve blood flow. This aortic cardiac assist device is a therapeutic treatment for early stage heart failure.
Anti-inflammatory Compound Development For The Treatment Of Heart Failure With Preserved Ejection Fraction
Funder
National Health and Medical Research Council
Funding Amount
$674,659.00
Summary
Heart failure with preserved ejection fraction (HFpEF) is a highly prevalent and rapidly growing heart condition with no proven effective therapies. We will develop novel drugs to treat HFpEF by focussing on heart scarring and inflammation. We have promising drug candidates that will be developed during the project, and these will be ready for for phase I clinical trial by the end of this grant. The outcome of this study is poised to address the significant unmet medical need.
Development Of A First-in-class Therapeutic For Protecting The Ischemic Heart
Funder
National Health and Medical Research Council
Funding Amount
$926,673.00
Summary
Heart disease is the leading cause of death globally. Heart attacks are the primary cause of death associated with heart disease. We have discovered a drug, Hi1a, that blocks the injury response of the heart when a heart attack happens. There are no other drugs currently available or in the discovery pipeline that address this problem. This proposal will use models of injury to the heart as well as safety studies to help develop Hi1a as a new drug for people who suffer from heart attacks.